New Delhi: The Serum Institute Of India has said that the potential Covid Vaccine Covishield could be available in India as early as January next year. SII which is working in collaboration with AstraZeneka on the Vaccine Development is in the advanced stages of trial.
The Chief Executive Officer of SII, Adar Poonawalla Wednesday said that the Coronavirus vaccine is likely to be available in the country if all regulatory approvals are in place by January 2021. Poonawala has said that based on the clinical trials being conducted in India and the United Kingdom the vaccine could be expected to be available in the country by s early as January. This will also depend on the vaccine’s proven immunogenic and efficacious.
While there have not been any safety issues in India or broad and thousands of people have been given vaccine shots, it will take two to three years to ascertain the long-term effects of the vaccine.
Poonawala also said that SII is in talks with government authorities over the pricing of the vaccine and hoped that it will be reasonable. SII hs capacity to produce as much as 60 to million doses per month which cn be extended to 100 million per month.